<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444169</url>
  </required_header>
  <id_info>
    <org_study_id>ULT-144</org_study_id>
    <nct_id>NCT02444169</nct_id>
  </id_info>
  <brief_title>Retrospective Evaluation of Combination Treatment With the Ulthera System</brief_title>
  <official_title>Retrospective Evaluation of Safety of Combination Treatment With the Ulthera® System and Xeomin, Belotero Balance, and Radiesse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ulthera, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective study to evaluate the Ulthera® System for its potential interaction with
      toxins and fillers. Up to 500 subjects will be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective, multi‐site study involving chart reviews of subjects who have
      received an Ultherapy treatment along with Radiesse®, Xeomin®, and/or Belotero® Balance
      within six months apart in the face and/or neck areas. Enrolled subjects will have received
      an Ultherapy treatment along with botulinum toxin A and/or filler treatment(s) within the
      last two years and with filler and toxin treatment occurring within 6 months before or after
      Ultherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Within 6 months before or after Ultherapy</time_frame>
    <description>An assessment of adverse events through chart review will evaluate the safety of combination treatments of Ultherapy with toxins/fillers.</description>
  </primary_outcome>
  <enrollment type="Actual">101</enrollment>
  <condition>Skin Laxity</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultherapy</intervention_name>
    <description>Focused ultrasound energy delivered below the surface of the skin.</description>
    <other_name>Ulthera System Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Incobotulinumtoxin A</intervention_name>
    <description>An injectable medicine used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.</description>
    <other_name>Xeomin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiesse</intervention_name>
    <description>An injectable dermal filler that temporarily adds volume to help smooth moderate to severe facial wrinkles and folds, such as nasolabial folds (the creases that extend from the corner of the nose to the corner of the mouth).</description>
    <other_name>Volumizing filler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Belotero Balance</intervention_name>
    <description>An injectable dermal filler to temporarily smooth out and fill in moderate-to-severe nasolabial folds (the folds or wrinkles that go from the side of the nose to the corner of the mouth).</description>
    <other_name>Dermal filler</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults between 25 and 70 years of age who have received an Ultherapy treatment and
        toxin/filler within the last two years within six months apart and meet the
        inclusion/exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age 25 to 70 years.

          -  Subject in good health

          -  Subject must have had an Ultherapy treatment and Merz branded neurotoxin/filler
             treatments within 6 months of one or more Ultherapy treatments.

          -  Subject must have had both Ultherapy and neurotoxin/filler within the last 2 years
             (since April 2013) and with toxin/filler treatment within 6 months proximity to the
             Ultherapy treatment date.

          -  Absence of physical or psychological conditions unacceptable to the investigator,
             especially those whom are contraindicated to receive treatments with Ultherapy,
             Belotero, Radiesse and/or Xeomin.

          -  Subjects who are identified with good photography, must have the ability to be
             contacted to provide authorization to disclose photographs for usage of previously
             taken photography, if photos are deemed worthy of publication.

        Exclusion Criteria:

          -  Subjects who have had any and all Ultherapy treatment(s) before April 2013.

          -  Subjects who have not received Radiesse®, Xeomin®, and/or Belotero Balance® within 6
             months of Ultherapy treatment date.

          -  Psychiatric drugs and/or diseases that in the investigators opinion would impair the
             subject from understanding the photo consent, if photos are chosen for publication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liss Misell, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ulthera, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aesthetic Plastic Surgical Institute</name>
      <address>
        <city>Laguna Beach</city>
        <state>California</state>
        <zip>92651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Cosmetic Laser Medical Associates of La Jolla</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Research Institute</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Laser Skin and Vein Institute</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2015</study_first_submitted>
  <study_first_submitted_qc>May 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cutis Laxa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>incobotulinumtoxinA</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

